Intellia Therapeutics Reports Positive Phase 3 Results In Hereditary Angioedema, Marking A Global First For In Vivo Gene Editing

Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both attacks and ongoing therapy for six-month efficac ...Read more